Literature DB >> 3813743

Factors associated with a poor outcome in tularemia.

R L Penn, G T Kinasewitz.   

Abstract

To identify the factors associated with a poor outcome, we reviewed the records of 28 patients with tularemia diagnosed between 1974 and 1984. Most of the patients were men between the ages of 35 and 45 years, who presented with ulceroglandular tularemia. Twelve patients had the anticipated rapid response to therapy, with resolution of their presenting symptoms within one week (group A). Surprisingly, the majority (16 [58%] of 28) had a more prolonged or fatal illness (group B). Group B patients more often had a serious underlying medical disorder, and waited longer before seeking medical attention. Only patients in group B presented with electrolyte or renal function abnormalities (31%), pneumonia and pleural effusions (25%), elevated serum creatine phosphokinase levels (25%), and Francisella tularensis bacteremia (12.5%). Sterile pyuria, however, was an unexpectedly frequent finding in both groups. Group B patients more often experienced a prolonged delay from the time of physician contact to therapy, and were not treated with an aminoglycoside; relapse (12.5%) and death (6.2%) occurred only in group B. Thus, earlier and more appropriate intervention by the physician may have prevented some of the increased morbidity in our patients. These findings suggest that rapid presumptive aminoglycoside therapy (gentamicin sulfate or streptomycin sulfate) should be considered soon after tularemia is suspected, especially for patients with serious underlying medical disorders.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3813743

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  10 in total

1.  Glandular tularemia with typhoidal features in a Manitoba child.

Authors:  P J Plourde; J Embree; F Friesen; G Lindsay; T Williams
Journal:  CMAJ       Date:  1992-06-01       Impact factor: 8.262

2.  Tularemia in Bursa, Turkey: 205 cases in ten years.

Authors:  S Helvaci; S Gedikoğlu; H Akalin; H B Oral
Journal:  Eur J Epidemiol       Date:  2000-03       Impact factor: 8.082

3.  Tularemia from domestic cats.

Authors:  W C Liles; R J Burger
Journal:  West J Med       Date:  1993-06

4.  The Francisella tularensis FabI enoyl-acyl carrier protein reductase gene is essential to bacterial viability and is expressed during infection.

Authors:  Luke C Kingry; Jason E Cummings; Kerry W Brookman; Gopal R Bommineni; Peter J Tonge; Richard A Slayden
Journal:  J Bacteriol       Date:  2012-11-09       Impact factor: 3.490

5.  Modeling inhalational tularemia: deliberate release and public health response.

Authors:  Joseph R Egan; Ian M Hall; Steve Leach
Journal:  Biosecur Bioterror       Date:  2011-11-01

6.  Post-exposure immunization against Francisella tularensis membrane proteins augments protective efficacy of gentamicin in a mouse model of pneumonic tularemia.

Authors:  Marjorie D Sutherland; Andrew W Goodyear; Ryan M Troyer; Jeffrey C Chandler; Steven W Dow; John T Belisle
Journal:  Vaccine       Date:  2012-05-28       Impact factor: 3.641

7.  The Cynomolgus Macaque Natural History Model of Pneumonic Tularemia for Predicting Clinical Efficacy Under the Animal Rule.

Authors:  Tina Guina; Lynda L Lanning; Kristian S Omland; Mark S Williams; Larry A Wolfraim; Stephen P Heyse; Christopher R Houchens; Patrick Sanz; Judith A Hewitt
Journal:  Front Cell Infect Microbiol       Date:  2018-04-04       Impact factor: 5.293

Review 8.  Vector-Borne Tularemia: A Re-Emerging Cause of Cervical Lymphadenopathy.

Authors:  Kaja Troha; Nina Božanić Urbančič; Miša Korva; Tatjana Avšič-Županc; Saba Battelino; Domen Vozel
Journal:  Trop Med Infect Dis       Date:  2022-08-16

Review 9.  New therapeutic approaches for treatment of tularaemia: a review.

Authors:  Sandrine Boisset; Yvan Caspar; Vivien Sutera; Max Maurin
Journal:  Front Cell Infect Microbiol       Date:  2014-03-28       Impact factor: 5.293

10.  Differentiation of Francisella tularensis Subspecies and Subtypes.

Authors:  Marilynn A Larson; Khalid Sayood; Amanda M Bartling; Jennifer R Meyer; Clarise Starr; James Baldwin; Michael P Dempsey
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.